Online first
Wytyczne / stanowisko ekspertów
Opublikowany online: 2024-06-26
Wyświetlenia strony 109
Wyświetlenia/pobrania artykułu 37
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Wytyczne Polskiego Towarzystwa Urologicznego, Polskiego Towarzystwa Ginekologów i Położników oraz Polskiego Towarzystwa Medycyny Rodzinnej dotyczące diagnostyki, terapii i postępowania w pozaszpitalnych zakażeniach dolnych dróg moczowych

Kajetan Juszczak12, Bartosz Dybowski34, Michał Holecki5, Waleria Hryniewicz6, Hanna Klimek7, Karolina Kłoda8, Piotr Sieroszewski7, Tomasz Drewa9

Streszczenie

Brak

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Bonkat G, Bartoletti R, Bruyère T, et al. EAU Guidelines on Urological Infections. Edn. presented at the EAU Annual Congress Milan 2023. EAU Guidelines Office, Arnhem 2023. https://uroweb.org/guidelines/urological-infections/chapter/the-guideline (15.01.2024).
  2. Hendy A, Bubenek-Turconi ŞI. The Diagnosis and Hemodynamic Monitoring of Circulatory Shock: Current and Future Trends. J Crit Care Med (Targu Mures). 2016; 2(3): 115–123.
  3. Tedja R, Wentink J, O'Horo JC, et al. Catheter-Associated Urinary Tract Infections in Intensive Care Unit Patients. Infect Control Hosp Epidemiol. 2015; 36(11): 1330–1334.
  4. Pothoven R. Management of urinary tract infections in the era of antimicrobial resistance. Drug Target Insights. 2023; 17: 126–137.
  5. Yang X, Chen H, Zheng Y, et al. Disease burden and long-term trends of urinary tract infections: A worldwide report. Front Public Health. 2022; 10: 888205.
  6. Hryniewicz W, Holecki M. (ed.). Rekomendacje diagnostyki, terapii i profilaktyki zakażeń układu moczowego u dorosłych. Narodowy Instytut Leków, Warszawa 2015.
  7. Zeng Z, Zhan J, Zhang K, et al. Global, regional, and national burden of urinary tract infections from 1990 to 2019: an analysis of the global burden of disease study 2019. World J Urol. 2022; 40(3): 755–763.
  8. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258): 1223–1249.
  9. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258): 1204–1222.
  10. Nicolle LE. Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. Urol Clin North Am. 2008; 35(1): 1–12, v.
  11. Deltourbe L, Lacerda Mariano L, Hreha TN, et al. The impact of biological sex on diseases of the urinary tract. Mucosal Immunol. 2022; 15(5): 857–866.
  12. Zeng G, Zhu W, Lam W, et al. Treatment of urinary tract infections in the old and fragile. World J Urol. 2020; 38(11): 2709–2720.
  13. Matthews SJ, Lancaster JW. Urinary tract infections in the elderly population. Am J Geriatr Pharmacother. 2011; 9(5): 286–309.
  14. Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA. 2014; 311(8): 844–854.
  15. Wernli D, Jørgensen PS, Harbarth S, et al. Antimicrobial resistance: The complex challenge of measurement to inform policy and the public. PLoS Med. 2017; 14(8): e1002378.
  16. Cassini A, Högberg LD, Plachouras D, et al. Burden of AMR Collaborative Group. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019; 19(1): 56–66.
  17. Godijk NG, McDonald SA, Altorf-van der Kuil W, et al. New methodology to assess the excess burden of antibiotic resistance using country-specific parameters: a case study regarding urinary tract infections. BMJ Open. 2023; 13(12): e064335.
  18. Jurałowicz E, Bartoszko-Tyczkowska A, Tyczkowska-Sieroń E, et al. Etiology and bacterial susceptibility to antibiotics in patients with recurrent lower urinary tract infections. Pol Arch Intern Med. 2020; 130(5): 373–381.
  19. Stefaniuk E, Suchocka U, Bosacka K, et al. Etiology and antibiotic susceptibility of bacterial pathogens responsible for community-acquired urinary tract infections in Poland. Eur J Clin Microbiol Infect Dis. 2016; 35(8): 1363–1369.
  20. Zhou Y, Zhou Z, Zheng L, et al. Urinary Tract Infections Caused by Uropathogenic : Mechanisms of Infection and Treatment Options. Int J Mol Sci. 2023; 24(13).
  21. Russo T, Marr C. Hypervirulent Klebsiella pneumoniae. Clinical Microbiology Reviews. 2019; 32(3).
  22. Turjeman A, Babich T, Pujol M, et al. COMBACTE MAGNET WP5 RESCUING Study Group and Study Sites. Risk factors for enterococcal urinary tract infections: a multinational, retrospective cohort study. Eur J Clin Microbiol Infect Dis. 2021; 40(9): 2005–2010.
  23. Clarke K, Hall CL, Wiley Z, et al. Catheter-Associated Urinary Tract Infections in Adults: Diagnosis, Treatment, and Prevention. J Hosp Med. 2020; 15(9): 552–556.
  24. Medina-Polo J, Naber KG, Bjerklund Johansen TE. Healthcare-associated urinary tract infections in urology. GMS Infect Dis. 2021; 9: Doc05.
  25. Schuler F, Barth PJ, Niemann S, et al. A Narrative Review on the Role of Bacteriuria in Bacteremia. Open Forum Infect Dis. 2021; 8(6): ofab158.
  26. Yoo JJ, Song JuS, Kim WB, et al. in Recurrent Urinary Tract Infection Is Associated with Dysbiosis of the Bladder Microbiome. J Clin Med. 2022; 11(9).
  27. Lotte R, Lotte L, Ruimy R. Actinotignum schaalii (formerly Actinobaculum schaalii): a newly recognized pathogen-review of the literature. Clin Microbiol Infect. 2016; 22(1): 28–36.
  28. Odabasi Z, Mert A. Candida urinary tract infections in adults. World J Urol. 2020; 38(11): 2699–2707.
  29. ROBERTS AP, BEARD RW. SOME FACTORS AFFECTING BACTERIAL INVASION OF BLADDER DURING PREGNANCY. Lancet. 1965; 1(7396): 1133–1136.
  30. Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America, American Society of Nephrology, American Geriatric Society. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005; 40(5): 643–654.
  31. Waltzer WC. The urinary tract in pregnancy. J Urol. 1981; 125(3): 271–276.
  32. Habak PJ, Griggs JR. Urinary Tract Infection in Pregnancy. In: Griggs JR. ed. StatPearls [Internet]. StatPearls Publishing, Florida 2023.
  33. Patterson TF, Andriole VT. Detection, significance, and therapy of bacteriuria in pregnancy. Update in the managed health care era. Infect Dis Clin North Am. 1997; 11(3): 593–608.
  34. Millar LK, Cox SM. Urinary tract infections complicating pregnancy. Infect Dis Clin North Am. 1997; 11(1): 13–26.
  35. Schaeffer AJ, Schaeffer EM. Infections of the urinary tract. In: Wein AJ. ed. Cambell-Walsh Urology. 10th edition. Saunders, an imprint of Elsevier Inc, Philadelphia 2012: 257–326.
  36. Hill JB, Sheffield JS, McIntire DD, et al. Acute pyelonephritis in pregnancy. Obstet Gynecol. 2005; 105(1): 18–23.
  37. Macejko AM, Schaeffer AJ. Asymptomatic bacteriuria and symptomatic urinary tract infections during pregnancy. Urol Clin North Am. 2007; 34(1): 35–42.
  38. Jamie WE, Edwards RK, Duff P. Antimicrobial susceptibility of Gram-negative uropathogens isolated from obstetric patients. Infect Dis Obstet Gynecol. 2002; 10(3): 123–126.
  39. Wing DA, Fassett MJ, Getahun D. Acute pyelonephritis in pregnancy: an 18-year retrospective analysis. Am J Obstet Gynecol. 2014; 210(3): 219.e1–219.e6.
  40. Cohen I, Veille JC, Calkins BM. Improved pregnancy outcome following successful treatment of chlamydial infection. JAMA. 1990; 263(23): 3160–3163.
  41. Gilbert GL, Garland SM, Fairley KF, et al. Bacteriuria due to ureaplasmas and other fastidious organisms during pregnancy: prevalence and significance. Pediatr Infect Dis. 1986; 5(6 Suppl): S239–S243.
  42. Agger WA, Siddiqui D, Lovrich SD, et al. Epidemiologic factors and urogenital infections associated with preterm birth in a midwestern U.S. population. Obstet Gynecol. 2014; 124(5): 969–977.
  43. Dzierżanowska-Fangrat K. (ed). Przewodnik antybiotykoterapii. Alfa-Medica Press, Bielsko-Biała 2023: 58–59.
  44. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012; 18(3): 268–281.
  45. Tacconelli E, Carrara E, Savoldi A, et al. WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018; 18(3): 318–327.
  46. Iredell J, Brown J, Tagg K. Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications. BMJ. 2016; 352: h6420.
  47. Mazzariol A, Bazaj A, Cornaglia G. Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review. J Chemother. 2017; 29(sup1): 2–9.
  48. Vachvanichsanong P, McNeil EB, Dissaneewate P. Extended-spectrum beta-lactamase and urinary tract infections. Epidemiol Infect. 2020; 149: e12.
  49. Doern C. Review of AmpC Beta-Lactamases in the Enterobacterales—Answers to Common Questions. Clinical Microbiology Newsletter. 2021; 43(10): 81–86.
  50. Markiewicz Z, Korska D, Popowska M. Antybiotyki w dobie narastającej lekooporności. Wydawnictwo Lekarskie PZWL, Warszawa 2021.
  51. Binsker U, Käsbohrer A, Hammerl JA. Global colistin use: a review of the emergence of resistant Enterobacterales and the impact on their genetic basis. FEMS Microbiol Rev. 2022; 46(1).
  52. Izdebski R, Baraniak A, Bojarska K, et al. Mobile MCR-1-associated resistance to colistin in Poland. J Antimicrob Chemother. 2016; 71(8): 2331–2333.
  53. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, et al. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat Rev Microbiol. 2019; 17(4): 203–218.
  54. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2006; 12 Suppl 1: 16–23.
  55. Wardal E, Żabicka D, Hryniewicz W, et al. VanA-Enterococcus faecalis in Poland: hospital population clonal structure and vanA mobilome. Eur J Clin Microbiol Infect Dis. 2022; 41(10): 1245–1261.
  56. Werner G, Coque TM, Franz CM, et al. Antibiotic resistant enterococci-tales of a drug resistance gene trafficker. Int J Med Microbiol. 2013; 303(6-7): 360–379.
  57. Hryniewicz W, Pawlik K, Deptuła A, Wanke-Rytt M. (ed.). Rekomendacje laboratoryjnej diagnostyki zakażeń. 1. Zakażenia układu moczowego. Narodowy Instytut Leków, Warszawa 2017.
  58. Yarbrough ML, Potter RF. Urine cultures. In: Leber AL, Burnham CAD. ed. Clinical Microbiology Procedure Handbook. ASM Press, Wiley 2023.
  59. McCallin S, Kessler TM, Leitner L. Management of uncomplicated urinary tract infection in the post-antibiotic era: select non-antibiotic approaches. Clin Microbiol Infect. 2023; 29(10): 1267–1271.
  60. Beerepoot MAJ, Geerlings SE, van Haarst EP, et al. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2013; 190(6): 1981–1989.
  61. Aziminia N, Hadjipavlou M, Philippou Y, et al. Vaccines for the prevention of recurrent urinary tract infections: a systematic review. BJU Int. 2019; 123(5): 753–768.
  62. Prattley S, Geraghty R, Moore M, et al. Role of Vaccines for Recurrent Urinary Tract Infections: A Systematic Review. Eur Urol Focus. 2020; 6(3): 593–604.
  63. Chen YY, Su TH, Lau HH. Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials. Int Urogynecol J. 2021; 32(1): 17–25.
  64. Canales J, Rada G. Are probiotics effective in preventing urinary tract infection? Medwave. 2018; 18(2): e7186.
  65. Grin PM, Kowalewska PM, Alhazzan W, et al. Lactobacillus for preventing recurrent urinary tract infections in women: meta-analysis. Can J Urol. 2013; 20(1): 6607–6614.
  66. Ng QX, Peters C, Venkatanarayanan N, et al. Use of Lactobacillus spp. to prevent recurrent urinary tract infections in females. Med Hypotheses. 2018; 114: 49–54.
  67. Fu Z, Liska D, Talan D, et al. Cranberry Reduces the Risk of Urinary Tract Infection Recurrence in Otherwise Healthy Women: A Systematic Review and Meta-Analysis. J Nutr. 2017; 147(12): 2282–2288.
  68. Luís Â, Domingues F, Pereira L. Can Cranberries Contribute to Reduce the Incidence of Urinary Tract Infections? A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Clinical Trials. J Urol. 2017; 198(3): 614–621.
  69. Wang CH, Fang CC, Chen NC, et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2012; 172(13): 988–996.
  70. Kyriakides R, Jones P, Somani BK. Role of D-Mannose in the Prevention of Recurrent Urinary Tract Infections: Evidence from a Systematic Review of the Literature. Eur Urol Focus. 2021; 7(5): 1166–1169.
  71. Cooper TE, Teng C, Howell M, et al. D-mannose for preventing and treating urinary tract infections. Cochrane Database Syst Rev. 2022; 8(8): CD013608.
  72. Nalliah S, Fong JS. H., Thor A.Y.Y., Lim O.H. The use of chemotherapeutic agents as prophylaxis for recurrent urinary tract infection in healthy nonpregnant women: a network meta-analysis. Indian J Urol. 2019; 35: 147–155.
  73. Ahmed H, Davies F, Francis N, et al. Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: systematic review and meta-analysis of randomised trials. BMJ Open. 2017; 7(5): e015233.
  74. Nicolle LE. Pivmecillinam in the treatment of urinary tract infections. Journal of Antimicrobial Chemotherapy. 2008; 62(1): 215–215.
  75. Hof H, Juretschke C. Nitroxoline: an option for the treatment of urinary tract infection with multi-resistant uropathogenic bacteria. Infection. 2019; 47(3): 493–495.
  76. Gupta K, Stamm WE. Outcomes associated with trimethoprim/sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI. Int J Antimicrob Agents. 2002; 19(6): 554–556.
  77. Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999; 29(4): 745–758.
  78. Hooton TM, Roberts PL, Stapleton AE. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA. 2012; 307(6): 583–589.
  79. Hooton TM, Scholes D, Gupta K, et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA. 2005; 293(8): 949–955.
  80. Wagenlehner FME, Wullt B, Perletti G. Antimicrobials in urogenital infections. Int J Antimicrob Agents. 2011; 38 Suppl: 3–10.
  81. Hooton TM. Recurrent urinary tract infection in women. Int J Antimicrob Agents. 2001; 17(4): 259–268.
  82. Poletajew S. Leczenie nawrotowych niepowikłanych zakażeń układu moczowego. Przegl Urol. 2016; 6(100).
  83. Cai T, Tamanini I, Collini L, et al. Management of Recurrent Cystitis in Women: When Prompt Identification of Risk Factors Might Make a Difference. Eur Urol Focus. 2022; 8(5): 1476–1482.
  84. Foxman B, Somsel P, Tallman P, et al. Urinary tract infection among women aged 40 to 65: behavioral and sexual risk factors. J Clin Epidemiol. 2001; 54(7): 710–718.
  85. Hooton TM. Prevention of recurrent urogenital tract infections in adult women. In: Naber TGK, Schaeffer AJ, Hyned CF. ed. EAU/International Consultation on Urological Infections. European Association of Urology, Arnhem 2010.
  86. Nicolle LE. Asymptomatic bacteriuria in the elderly. Infect Dis Clin North Am. 1997; 11(3): 647–662.
  87. Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. Expert Opin Drug Saf. 2014; 13(12): 1569–1581.
  88. Dashe JS, Gilstrap LC. Antibiotic use in pregnancy. Obstet Gynecol Clin North Am. 1997; 24(3): 617–629.
  89. Gilstrap LC, Ramin SM. Urinary tract infections during pregnancy. Obstet Gynecol Clin North Am. 2001; 28(3): 581–591.
  90. Nørgaard M, Skriver MV, Sørensen HT, et al. Risk of miscarriage for pregnant users of pivmecillinam: a population-based case-control study. APMIS. 2008; 116(4): 278–283.
  91. Insulander M, Lebbad M, Stenström TA, et al. An outbreak of cryptosporidiosis associated with exposure to swimming pool water. Scand J Infect Dis. 2005; 37(5): 354–360.
  92. Gilstrap LC, Leveno KJ, Cunningham FG, et al. Renal infection and pregnancy outcome. Am J Obstet Gynecol. 1981; 141(6): 709–716.
  93. Mazor-Dray E, Levy A, Schlaeffer F, et al. Maternal urinary tract infection: is it independently associated with adverse pregnancy outcome? J Matern Fetal Neonatal Med. 2009; 22(2): 124–128.
  94. Pfau A, Sacks TG. Effective prophylaxis for recurrent urinary tract infections during pregnancy. Clin Infect Dis. 1992; 14(4): 810–814.
  95. Albert X, Huertas I, Pereiró II, et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004; 2004(3): CD001209.
  96. Schneeberger C, Geerlings SE, Middleton P, et al. Interventions for preventing recurrent urinary tract infection during pregnancy. Cochrane Database Syst Rev. 2012; 11(7): CD009279.
  97. Vazquez JC, Villar J, Vazquez JC, et al. Treatments for symptomatic urinary tract infections during pregnancy. Cochrane Database Syst Rev. 2000(3): CD002256.
  98. Ansaldi Y, Martinez de Tejada Weber B. Urinary tract infections in pregnancy. Clin Microbiol Infect. 2023; 29(10): 1249–1253.
  99. Lutay N, Ambite I, Grönberg Hernandez J, et al. Bacterial control of host gene expression through RNA polymerase II. J Clin Invest. 2013; 123(6): 2366–2379.
  100. Cai T, Mazzoli S, Mondaini N, et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis. 2012; 55(6): 771–777.
  101. Tencer J. Asymptomatic bacteriuria--a long-term study. Scand J Urol Nephrol. 1988; 22(1): 31–34.
  102. Harding GKM, Zhanel GG, Nicolle LE, et al. Manitoba Diabetes Urinary Tract Infection Study Group. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med. 2002; 347(20): 1576–1583.
  103. Silver SA, Baillie L, Simor AE. Positive urine cultures: A major cause of inappropriate antimicrobial use in hospitals? Can J Infect Dis Med Microbiol. 2009; 20(4): 107–111.
  104. Trautner BW. Asymptomatic bacteriuria: when the treatment is worse than the disease. Nat Rev Urol. 2011; 9(2): 85–93.
  105. Moradi M, Abbasi M, Moradi A, et al. Effect of antibiotic therapy on asymptomatic bacteriuria in kidney transplant recipients. Urol J. 2005; 2(1): 32–35.
  106. El Amari EB, Hadaya K, Bühler L, et al. Outcome of treated and untreated asymptomatic bacteriuria in renal transplant recipients. Nephrol Dial Transplant. 2011; 26(12): 4109–4114.
  107. Green H, Rahamimov R, Goldberg E, et al. Consequences of treated versus untreated asymptomatic bacteriuria in the first year following kidney transplantation: retrospective observational study. Eur J Clin Microbiol Infect Dis. 2013; 32(1): 127–131.
  108. Origüen J, López-Medrano F, Fernández-Ruiz M, et al. Should Asymptomatic Bacteriuria Be Systematically Treated in Kidney Transplant Recipients? Results From a Randomized Controlled Trial. Am J Transplant. 2016; 16(10): 2943–2953.
  109. Bonkat G, Widmer AF, Rieken M, et al. Microbial biofilm formation and catheter-associated bacteriuria in patients with suprapubic catheterisation. World J Urol. 2013; 31(3): 565–571.
  110. Tenke P, Kovacs B, Bjerklund Johansen TE, et al. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int J Antimicrob Agents. 2008; 31 Suppl 1: S68–S78.
  111. Cooper FPM, Alexander CE, Sinha S, et al. Policies for replacing long-term indwelling urinary catheters in adults. Cochrane Database Syst Rev. 2016; 7(7): CD011115.
  112. Dasgupta R, Grabe M. Preoperative antibiotics before endourologic surgery: current recommendations. J Endourol. 2009; 23(10): 1567–1570.
  113. Sobel JD, Kauffman CA, McKinsey D, et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis. 2000; 30(1): 19–24.
  114. Sousa R, Muñoz-Mahamud E, Quayle J, et al. Is asymptomatic bacteriuria a risk factor for prosthetic joint infection? Clin Infect Dis. 2014; 59(1): 41–47.